BSE Live
Mar 11, 16:01Prev. Close
2237.80
Open Price
2232.10
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 11, 15:59Prev. Close
2237.70
Open Price
2243.90
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
2243.80 (1)
| Key Financial Ratios of Mankind Pharma (in Rs. Cr.) | Mar 20 | |
| Per Share Ratios | ||
| Basic EPS (Rs.) | 25.72 | |
| Diluted EPS (Rs.) | 25.72 | |
| Cash EPS (Rs.) | 28.55 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 91.65 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 91.65 | |
| Revenue from Operations/Share (Rs.) | 146.41 | |
| PBDIT/Share (Rs.) | 38.62 | |
| PBIT/Share (Rs.) | 36.15 | |
| PBT/Share (Rs.) | 35.60 | |
| Net Profit/Share (Rs.) | 26.08 | |
| NP After MI And SOA / Share (Rs.) | 25.72 | |
| Profitability Ratios | ||
| PBDIT Margin (%) | 26.37 | |
| PBIT Margin (%) | 24.69 | |
| PBT Margin (%) | 24.31 | |
| Net Profit Margin (%) | 17.81 | |
| NP After MI And SOA Margin (%) | 17.56 | |
| Return on Networth/Equity (%) | 29.56 | |
| Return on Capital Employed (%) | 37.96 | |
| Return on Assets (%) | 20.31 | |
| Total Debt/Equity (X) | 0.04 | |
| Asset Turnover Ratio (%) | 0.00 | |
| Liquidity Ratios | ||
| Current Ratio (X) | 2.24 | |
| Quick Ratio (X) | 1.53 | |
| Inventory Turnover Ratio (X) | 0.00 | |
| Dividend Payout Ratio (NP) (%) | 29.35 | |
| Dividend Payout Ratio (CP) (%) | 26.77 | |
| Earnings Retention Ratio (%) | 70.65 | |
| Cash Earnings Retention Ratio (%) | 73.23 | |
| Coverage Ratios | ||
| Interest Coverage Ratios (%) | 70.42 | |
| Interest Coverage Ratios (Post Tax) (%) | 70.42 | |
| Valuation Ratios | ||
| Enterprise Value (Cr.) | 0.00 | |
| EV/Net Operating Revenue (X) | 0.00 | |
| EV/EBITDA (X) | 0.00 | |
| MarketCap/Net Operating Revenue (X) | 0.00 | |
| Retention Ratios (%) | 70.64 | |
| Price/BV (X) | 0.00 | |
| Price/Net Operating Revenue | 0.00 | |
| Earnings Yield | 0.00 |
11.03.2026
10.03.2026
09.03.2026
04.03.2026
Natco Pharma shares rise 2% on Pomalidomide capsules launch in US
05.02.2026
Mankind Pharma Consolidated December 2025 Net Sales at Rs 3,567.20 crore, up 10.44% Y-o-Y
05.02.2026
Mankind Pharma Standalone December 2025 Net Sales at Rs 2,632.68 crore, up 9.85% Y-o-Y
12.11.2025
Mankind Pharma Standalone September 2025 Net Sales at Rs 2,608.78 crore, up 3.12% Y-o-Y
07.11.2025
Mankind Pharma Consolidated September 2025 Net Sales at Rs 3,697.16 crore, up 20.17% Y-o-Y
05.02.2026
Mankind Pharma Consolidated December 2025 Net Sales at Rs 3,567.20 crore, up 10.44% Y-o-Y
05.02.2026
Mankind Pharma Standalone December 2025 Net Sales at Rs 2,632.68 crore, up 9.85% Y-o-Y
12.11.2025
Mankind Pharma Standalone September 2025 Net Sales at Rs 2,608.78 crore, up 3.12% Y-o-Y
07.11.2025
Mankind Pharma Consolidated September 2025 Net Sales at Rs 3,697.16 crore, up 20.17% Y-o-Y
25.04.2023
24.04.2023
11.03.2026
Targeting mistake led to US missile strike on Iranian school: Report
11.03.2026
Govt considering sustainable data centre policy: Karnataka IT Minister Priyank Kharge
11.03.2026
Panel will be formed to implement Supreme Court order allowing passive euthanasia to youth: AIIMS
11.03.2026
Iran 'welcome to compete' in World Cup, says US President Trump
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
24.10.2025
22.05.2025
Sun Pharma Q4 net profit declines 19% to Rs 2,154 crore, firm declares Rs 5.50 dividend
07.11.2025
27.10.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
24.10.2025